High-risk subgroups of patients with non-Q wave myocardial infarction based on direction and severity of ST segment deviation.
Am HeartJ 1987;114:1110-19. This letter was shown to the authors, who reply as follows: SIR,-As Dr Jolobe states in his letter, the adverse prognostic significance of ST segment depression in patients with non-Q wave myocardial infarction is well recognised. In our study, however, the patient group was representative of all patients admitted with myocardial infarction (MI). Of 57 patients whose admission and follow up electrocardiograms were available for analysis 13, (23%) had a non-Q wave -MI and of these six presented with ST segment depression. The mean left ventricular ejection fraction (LVEF) in those patients with non-Q wave MI and ST depression was 37*5% compared with 45-7% in those who presented with non-Q wave MI and ST elevation. It is notable that the mean modified Peel index, which includes a score for post-infarction angina, was 10*7 in the ST depression group and 7-3 in ST elevation group. In the patients who had a Qwave MI, 17 
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About two thirds of patients who present with ST depression or T wave inversion on an admission ECG will have confirmed acute myocardial infarction on discharge.7 The patients with a discharge diagnosis of infarction are potentially those who would benefit most from thrombolytic therapy.4 It has been shown in theory8 and in practice9 that the use of early immunoassay of creatine kinase MB can achieve 94% sensitivity and specificity for prediction of the discharge diagnosis of infarction.
A subgroup analysis that might yield valuable information could be undertaken by the ISIS-3 coordinators. In ISIS-3, 9158 patients were enrolled as having an "uncertain" indication for thrombolytic therapy; 70% of these had an admission ECG criterion other than ST elevation.'0 Fifty nine per cent of the patients in the whole "uncertain" group had a discharge diagnosis of myocardial infarction. Thirty five day mortality was 8-3% in the whole "uncertain" group and 11 4% in those with a discharge diagnosis of infarction. What was the mortality for thrombolytic treatment and what for placebo in this last group? As far as we are aware these figures have never been published. IAN 
